small molecule

LUPKYNIS

VOCLOSPORIN

Loss of exclusivityDecember 2037latest FDA-listed patent expiry

CompanyAurinia Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	LUPKYNIS
Active ingredient	VOCLOSPORIN
Strength	7.9MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	January 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11622991	December 2037	use U-3056
10286036	December 2037	use U-3056
7332472	October 2027	substance, product

Regulatory exclusivity

Code	Expires
NCE	January 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.